Hyperuricemia in patients with chronic kidney disease: When and what to treat?
Marian Goicoechea1, Rodrigo García-Marina2
1Servicio de Nefrología, Hospital General Universitario Gregorio Marañón, Spain; Instituto de Investigación Sanitaria Gregorio Marañon, Spain; RICORS 2040, Instituto de Salud Carlos III, Spain.
Insights
Patients with chronic kidney disease (CKD) and gout should use hypouricemic drugs to lower uric acid (UA) levels. Treatment for asymptomatic hyperuricemia in CKD is not currently supported by clinical trials.
Area of Science:
- Nephrology
- Rheumatology
- Cardiology
Background:
- Hyperuricemia is linked to gout, kidney disease, hypertension, and cardiovascular disease.
- Gout in chronic kidney disease (CKD) patients requires management of uric acid (UA) levels.
- Asymptomatic hyperuricemia poses risks for cardiovascular and renal health.
Purpose of the Study:
- To outline treatment strategies for hyperuricemia in CKD patients.
- To define target UA levels for CKD patients experiencing gout.
- To evaluate the evidence for treating asymptomatic hyperuricemia in CKD.
Main Methods:
- Review of current clinical guidelines and trial data.
- Analysis of therapeutic options for hyperuricemia in CKD.
- Assessment of risks and benefits of hypouricemic drug use.
Main Results:
- CKD patients with gout should aim for UA < 6 mg/dl (or < 5 mg/dl if tophi present).
- Allopurinol and febuxostat are recommended hypouricemic agents for CKD patients with gout.
- Low starting doses are advised, with gradual increases based on tolerance.
- Current evidence does not support treating asymptomatic hyperuricemia in CKD.
Conclusions:
- Hypouricemic therapy is crucial for CKD patients with gout to prevent disease progression.
- Allopurinol and febuxostat are effective and safe options when initiated cautiously.
- Further research is needed to clarify the role of treating asymptomatic hyperuricemia in CKD.
Abstract:
Hyperuricemia is frequently associated with gout, renal disease, arterial hypertension and high cardiovascular disease. All CKD patients with a first episode of gout should be treated with hypouricemic drugs to achieve baseline UA levels of less than 6 mg/dl (< 5 mg/dl if tophi are present). The hypouricemic drugs of choice in patients with CKD are allopurinol and febuxostat, always starting treatment with low doses that can be progressively increased according to tolerance. Asymptomatic hyperuricemia increases the risk of arterial hypertension, cardiovascular disease and renal disease, but at present published clinical trials do not support the treatment of asymptomatic hyperuricemia in patients with CKD.
Related Concept Videos
Urinary Tract Calculi III: Medical Management
Chronic Kidney Disease III: Interprofessional Care
Urinary Tract Calculi IV: Nutrition Therapy and Prevention
Chronic Kidney Disease IV: Nursing Management
Acute Kidney Injury V: Interprofessional Care
Urinary Tract Calculi V: Nursing Management
![Quantitative SERS Detection of Uric Acid via Formation of Precise Plasmonic Nanojunctions within Aggregates of Gold Nanoparticles and Cucurbit[n]uril](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F61682.jpg&w=3840&q=50)

